Peptide nucleic acids (PNAs), developed by Peter Nielsen in the early 90’s, constitute synthetic analogues of DNA and RNA, where the phosphodiester backbone of these natural oligonucleotides (ON) is replaced by a pseudopeptide structure. PNAs hybridize with complementary nucleic acid segments with higher affinity and specificity than natural ON, interfering with higher efficiency with target genes. Moreover, the unnatural backbone of PNAs makes them highly resistant to enzymatic degradation.
These characteristics make them valuable tools for various applications, from diagnostics to therapeutics. Limitations to their versatility include poor water solubility and low nuclear targeting capability. However, these have been successfully circumvented by the introduction of chemical modifications to PNA sequences, such as cell-penetrating peptides, which have been proven to be highly valuable in drug delivery and gene therapy. Just as for peptides, PNA can be obtained through standard SPPS procedures.
Register for this webinar to hear a brief introduction of these ON analogues and address the synthesis of a target peptide-PNA sequence, particularly highlighting the differences between manual and automated approaches, using Symphony® X peptide synthesizer from Gyros Protein Technologies, and the challenges we faced during this process.
Dr. Luísa Aguiar, Post-Doctoral researcher at Paula Gomes Lab, University of Porto
Dr. Luisa Aguiar first came in contact with bioactive peptides in her master’s thesis in Chemistry, which she developed in Prof. Paula Gomes’s Lab (www.fc.up.pt/pessoas/pgomes/) at the Faculty of Sciences of the University of Porto, Portugal. In this project, she synthesized cell-penetrating peptides that were able to promote efficient intracellular delivery of oligonucleotides for gene therapy.
She next pursued her Ph.D. in sustainable chemistry in the same lab, which she completed in 2019, with a doctoral project focused on development of bioactive peptides modified with antimalarial drugs to try to improve their biological activity. Since then, she has been working more closely with antimicrobial peptides derived from snake venoms and, in parallel, dedicated to implementing the synthesis of peptide-nucleic acids in the laboratory.Message Presenter
Who Should Attend?
- Senior Scientists
- Technical Leaders
- PhD Candidates
What You Will Learn
In this webinar, participants will learn about:
- How to overcome the challenges posed by the synthesis of PNAs, such as their propensity to aggregate
- How to facilitate the purification step and increase the yield of the target product
Gyros Protein Technologies
Gyros Protein Technologies enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the PurePep® Chorus, Symphony® X, and Sonata® XT. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.